Tie-2 modulators - Pipeline Insight, 2024

This “Tie-2 modulators - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Tie-2 modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tie-2 modulators Understanding

Tie-2 modulators: Overview

Angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) are peptide ligands for the tyrosine kinase with Ig (immunoglobulin) and EGF (epidermal growth factor) homology domains 2 (Tie2) receptor. Ang1 is a Tie2 receptor agonist while Ang2 is a contextual antagonist, blocking Tie2 signaling in most contexts but capable of enhancing Tie2 signaling under specific conditions. The Tie2 signaling pathway is specific to vascular endothelial cells as is the VEGF pathway. However, while the VEGF pathway promotes the initiation of angiogenesis, the Tie2 signaling pathway is more active in maintenance of vascular health, promoting endothelial cell (EC) survival, maturation, and stability. There are 5 key components of the Tie2 pathway relevant to ocular angiogenesis: the Tie1 and Tie2 receptors, angiopoietin-1 and -2, and the vascular endothelial tyrosine phosphatase (VE-PTP) receptor.

Tie-2 modulators - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tie-2 modulators pipeline landscape is provided which includes the disease overview and Tie-2 modulators treatment guidelines. The assessment part of the report embraces, in depth Tie-2 modulators commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tie-2 modulators collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Tie-2 modulators R&D. The therapies under development are focused on novel approaches to treat/improve Tie-2 modulators.

Tie-2 modulators Emerging Drugs Chapters

This segment of the Tie-2 modulators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tie-2 modulators Emerging Drugs

Sitravatinib: Mirati TherapeuticsSitravatinib is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. Sitravatinib is being evaluated in combination with nivolumab (OPDIVO), an anti-PD-1 checkpoint inhibitor, in patients whose cancers have progressed despite treatment with a checkpoint inhibitor. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are resistant to prior immune checkpoint inhibitor therapy and progressed on platinum doublet therapy, including the ongoing potentially registration-enabling Phase III trial of sitravatinib in combinations with a checkpoint inhibitor in non-small cell lung cancer (NSCLC). In addition, sitravatinib in combination with checkpoint inhibitors are being evaluated in selected checkpoint inhibitor naïve patients.

Razuprotafib: Aadi BiosciencesRazuprotafib binds to and inhibits vascular endothelial protein tyrosine phosphatase (“VE-PTP”), an important negative regulator of Tie2. Decreased Tie2 activity contributes to vascular instability in many diseases including diabetes and more recently has been shown to contribute to the development of increased IOP and glaucoma. Razuprotafib activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiopoietin-1 (agonist) or angiopoietin-2 (antagonist) and we believe that it may be the most efficient pharmacologic approach to maintain normal Tie2 activation.

Tie-2 modulators: Therapeutic Assessment

This segment of the report provides insights about the different Tie-2 modulators drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tie-2 modulators

There are approx. 10+ key companies which are developing the therapies for Tie-2 modulators. The companies which have their Tie-2 modulators drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tie-2 modulators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tie-2 modulators: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tie-2 modulators therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tie-2 modulators drugs.

Tie-2 modulators Report Insights

• Tie-2 modulators Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tie-2 modulators Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tie-2 modulators drugs?
• How many Tie-2 modulators drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tie-2 modulators?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tie-2 modulators therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tie-2 modulators and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ipsen
• Mirati Therapeutics
• Array BioPharma
• Aadi Biosciences
• PharmAbcine
• Deciphera Pharmaceuticals

Key Products

• Cabozantinib
• Sitravatinib
• ARRY 614
• Razuprotafib
• PMC-403
• PMC-402
• Rebastinib

This product will be delivered within 1-3 business days.